China's CDE Adds YolTech's YOLT‑201 and Qilu Pharmaceutical's QLS2416 to CARE‑Extension Pilot Program – In Vivo Gene Editing and Trispecific T‑Cell Engager Win Regulatory Fast‑Track Attention
Policy / Regulatory

China’s CDE Adds YolTech’s YOLT‑201 and Qilu Pharmaceutical’s QLS2416 to CARE‑Extension Pilot Program – In Vivo Gene Editing and Trispecific T‑Cell Engager Win Regulatory Fast‑Track Attention

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued a notice announcing the inclusion of YolTech Therapeutics' YOLT‑201 and Qilu Pharmaceutical's QLS2416 in the "CARE‑Extension"…

Takeda's Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China's First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas
CompanyDrug

Takeda’s Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China’s First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

NMPA Approves New Indication for J&J's Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line
CompanyDrug

NMPA Approves New Indication for J&J’s Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

Novo Nordisk's NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China
CompanyDrug

Novo Nordisk’s NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China

Bayer's Sunharbo (Asundexian) Secures NMPA Approval in China – World's First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA
CompanyDrug

Bayer’s Sunharbo (Asundexian) Secures NMPA Approval in China – World’s First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance
CompanyDrug

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

TenNor Therapeutics Reports Multiple R&D Milestones for Rifasutenizol and Rifaquinone – NDA Supplementary Package Complete as First‑in‑Class Triple‑Target Agent Advances Against Device‑Associated Infections
CompanyDrug

TenNor Therapeutics Reports Multiple R&D Milestones for Rifasutenizol and Rifaquinone – NDA Supplementary Package Complete as First‑in‑Class Triple‑Target Agent Advances Against Device‑Associated Infections

CureGene Pharmaceutical and Walvax Biotechnology Sign Strategic MOU – Full‑Chain Alliance to Accelerate Innovative Nucleic Acid Drugs from AI‑Enabled mRNA R&D to Large‑Scale Manufacturing
CompanyDeals

CureGene Pharmaceutical and Walvax Biotechnology Sign Strategic MOU – Full‑Chain Alliance to Accelerate Innovative Nucleic Acid Drugs from AI‑Enabled mRNA R&D to Large‑Scale Manufacturing

Jiangsu Hengrui's SHR‑1918 (Aiqingda) Approved by China's NMPA for HoFH – China's First Independently Developed ANGPTL3 Monoclonal Antibody Cuts LDL‑C by 64.2 % in Phase III
CompanyDrug

Jiangsu Hengrui’s SHR‑1918 (Aiqingda) Approved by China’s NMPA for HoFH – China’s First Independently Developed ANGPTL3 Monoclonal Antibody Cuts LDL‑C by 64.2 % in Phase III

AbbVie's Rinvoq Wins NMPA Approval for Non‑Segmental Vitiligo – First and Only Systemic Therapy for the Disease in China
CompanyDrug

AbbVie’s Rinvoq Wins NMPA Approval for Non‑Segmental Vitiligo – First and Only Systemic Therapy for the Disease in China

JW Therapeutics Transfers Greater China and ASEAN Rights in Solid Tumor Cell Therapy Programs to Eureka – Deal Includes GPC3 and AFP‑Targeted TCR‑T Candidates

JW Therapeutics Transfers Greater China and ASEAN Rights in Solid Tumor Cell Therapy Programs to Eureka – Deal Includes GPC3 and AFP‑Targeted TCR‑T Candidates

JW Therapeutics (HKG: 2126) announced that it has entered into a license and transfer agreement with Eureka Therapeutics and its affiliates covering Greater China and ASEAN regional rights to certain solid tumor cell therapy projects previously acquired by the company,…

CSPC Innovation Pharmaceutical's ADC Candidate SYS6062 Wins NMPA Clinical Trial Approval – Advances in Advanced Solid Tumors

CSPC Innovation Pharmaceutical’s ADC Candidate SYS6062 Wins NMPA Clinical Trial Approval – Advances in Advanced Solid Tumors

Autobio Diagnostics and Haier Biomedical Sign Strategic Cooperation Agreement – AI‑Driven Alliance to Build Holistic Smart Laboratory Solutions Across IVD, Automation, and Medical Informatization
CompanyDeals

Autobio Diagnostics and Haier Biomedical Sign Strategic Cooperation Agreement – AI‑Driven Alliance to Build Holistic Smart Laboratory Solutions Across IVD, Automation, and Medical Informatization

RemeGen Expands Vor Bio Licensing Deal to Include RC298 – Next‑Generation BAFF/APRIL Dual Inhibitor Secures USD 56 Million Upfront and Up to USD 300 Million in Milestones
CompanyDeals

RemeGen Expands Vor Bio Licensing Deal to Include RC298 – Next‑Generation BAFF/APRIL Dual Inhibitor Secures USD 56 Million Upfront and Up to USD 300 Million in Milestones

LEO Pharma's Anzupgo Approved by China's NMPA for Chronic Hand Eczema – World's First and Only Topical Pan‑JAK Inhibitor for Moderate‑to‑Severe CHE
CompanyDrug

LEO Pharma’s Anzupgo Approved by China’s NMPA for Chronic Hand Eczema – World’s First and Only Topical Pan‑JAK Inhibitor for Moderate‑to‑Severe CHE

Exegenesis Bio and Ascidian Therapeutics Forge Strategic Alliance – Pairing AAV Capsid Engineering with RNA Exon Editing for Next‑Generation Gene Medicine Delivery
CompanyDeals

Exegenesis Bio and Ascidian Therapeutics Forge Strategic Alliance – Pairing AAV Capsid Engineering with RNA Exon Editing for Next‑Generation Gene Medicine Delivery

TYK Medicines' Asandeutertinib (TY‑9591) Set to Ship First Commercial Batch – Qilu Pharmaceutical to Launch China Sales of the NMPA‑Approved EGFR‑TKI
CompanyDrug

TYK Medicines’ Asandeutertinib (TY‑9591) Set to Ship First Commercial Batch – Qilu Pharmaceutical to Launch China Sales of the NMPA‑Approved EGFR‑TKI

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Fuzhou Luyan Pharmacy Secures Exclusive Greater China Rights to French Synergia Brand in Strategic Partnership with Curae LAB
CompanyDeals

Fuzhou Luyan Pharmacy Secures Exclusive Greater China Rights to French Synergia Brand in Strategic Partnership with Curae LAB

Fuzhou Luyan Pharmacy Co., Ltd. ("Luyan Pharma") signed an exclusive strategic cooperation agreement with Curae LAB, a subsidiary of the French GTH Group, for the Synergia brand in Greater China.…

Hangzhou Eli Radiopharma Closes Nearly RMB 400 Million Series A Round – Capital Earmarked for Radiopharmaceutical Pipeline and Radiotheranostic Platform Buildout
CompanyDeals

Hangzhou Eli Radiopharma Closes Nearly RMB 400 Million Series A Round – Capital Earmarked for Radiopharmaceutical Pipeline and Radiotheranostic Platform Buildout

Revvity and BioMap Sign Strategic AI4S Partnership – A "Dry‑Wet" Closed‑Loop Alliance to Accelerate AI‑Empowered Life Sciences
CompanyDeals

Revvity and BioMap Sign Strategic AI4S Partnership – A “Dry‑Wet” Closed‑Loop Alliance to Accelerate AI‑Empowered Life Sciences

AstraZeneca Acquires Omniose – Vaccine Bioconjugation Specialist Bolsters Bacterial Threat Defense Within Infectious Disease Unit
CompanyDeals

AstraZeneca Acquires Omniose – Vaccine Bioconjugation Specialist Bolsters Bacterial Threat Defense Within Infectious Disease Unit

MindRank and BoomRay Forge Strategic Alliance to Build AI‑Driven Radioligand Conjugates – Cyclic Peptide RDCs Target First‑in‑Class Oncology Assets
CompanyDeals

MindRank and BoomRay Forge Strategic Alliance to Build AI‑Driven Radioligand Conjugates – Cyclic Peptide RDCs Target First‑in‑Class Oncology Assets

- Advertisement -
RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus
CompanyDeals

RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus

Sanyou Biopharmaceuticals Completes Series C Financing of Nearly RMB 100 Million – Zero2IPO Industry Investment Fund Backs AI‑Driven Drug Discovery Platform
CompanyDeals

Sanyou Biopharmaceuticals Completes Series C Financing of Nearly RMB 100 Million – Zero2IPO Industry Investment Fund Backs AI‑Driven Drug Discovery Platform

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares
CompanyDeals

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
Policy / Regulatory

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

The Comprehensive Department of China's National Medical Products Administration (NMPA) has released the Measures for the Implementation of Drug Market Exclusivity (Draft for Comment), proposing a unified exclusivity regime that…

Insurance Association of China Unveils First Commercial Insurance Recommended Drug List – 58 Drugs and Devices, Nearly 60% Outside the NRDL
Policy / Regulatory

Insurance Association of China Unveils First Commercial Insurance Recommended Drug List – 58 Drugs and Devices, Nearly 60% Outside the NRDL

FDA Flags Potential NAION Vision‑Loss Risk with GLP‑1 RA Medications – Labeling Update Required Across the Drug Class
CompanyDrug

FDA Flags Potential NAION Vision‑Loss Risk with GLP‑1 RA Medications – Labeling Update Required Across the Drug Class

China Issues Joint Notice to Accelerate Hospital Adoption of Innovative Drugs – NRDL and Commercial Insurance Lists Get Fast-Track Deployment
Policy / Regulatory

China Issues Joint Notice to Accelerate Hospital Adoption of Innovative Drugs – NRDL and Commercial Insurance Lists Get Fast-Track Deployment

More News

Abbisko's PIMJETMI (Pimicotinib) Wins FDA Approval for Symptomatic Tenosynovial Giant Cell Tumor – First U.S. Green Light for the China‑Born CSF‑1R Inhibitor
CompanyDrug

Abbisko’s PIMJETMI (Pimicotinib) Wins FDA Approval for Symptomatic Tenosynovial Giant Cell Tumor – First U.S. Green Light for the China‑Born CSF‑1R Inhibitor

Evopoint Biosciences' Imipenem/Cilastatin/Funobactam Wins NMPA Marketing Approval – Class 1 Triple‑Combination Antibiotic for HABP and VABP
CompanyDrug

Evopoint Biosciences’ Imipenem/Cilastatin/Funobactam Wins NMPA Marketing Approval – Class 1 Triple‑Combination Antibiotic for HABP and VABP

Eli Lilly's Foundayo (Orforglipron) Wins NMPA Approval – First Oral GLP‑1 Receptor Agonist for Adult Weight Management in China
CompanyDrug

Eli Lilly’s Foundayo (Orforglipron) Wins NMPA Approval – First Oral GLP‑1 Receptor Agonist for Adult Weight Management in China

Amgen's Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren's Disease Activity
CompanyDrug

Amgen’s Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren’s Disease Activity

Pfizer and Blackstone Life Sciences Strike USD 1.5 Billion Co‑Funding Deal for Berobenatide – Potential First‑in‑Class Monthly GLP‑1 for Obesity
Others

Pfizer and Blackstone Life Sciences Strike USD 1.5 Billion Co‑Funding Deal for Berobenatide – Potential First‑in‑Class Monthly GLP‑1 for Obesity

Lepu Medical's Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World's First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia
CompanyDrug

Lepu Medical’s Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World’s First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia

Hengrui Wins NMPA Trial Clearances for Two Assets – SHR‑1139 Bispecific Antibody and First‑of‑Kind Oral Lp(a) Inhibitor HRS‑5346
CompanyDrug

Hengrui Wins NMPA Trial Clearances for Two Assets – SHR‑1139 Bispecific Antibody and First‑of‑Kind Oral Lp(a) Inhibitor HRS‑5346

FDA Approves Bayer's Sunharbo (Asundexian) – World's First FXIa Inhibitor for Secondary Stroke Prevention
CompanyDrug

FDA Approves Bayer’s Sunharbo (Asundexian) – World’s First FXIa Inhibitor for Secondary Stroke Prevention

Show More